<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11861">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00538512</url>
  </required_header>
  <id_info>
    <org_study_id>FLUVACS</org_study_id>
    <nct_id>NCT00538512</nct_id>
  </id_info>
  <brief_title>Comparative Study of Influenza Vaccines in Adults, FLUVACS-year 4</brief_title>
  <acronym>FLUVACS</acronym>
  <official_title>Comparative Study of Influenza Vaccines in Adults, FLUVACS-year 4</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi Pasteur MSD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the absolute (versus placebo) and relative (one
      vaccine compared to the other) efficacies of the live attenuated and inactivated influenza
      vaccines in preventing laboratory confirmed symptomatic influenza caused by circulating
      strains whether similar or dissimilar to strains included in the vaccines.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Laboratory-confirmed (Culture and/or PCR) Symptomatic Influenza</measure>
    <time_frame>one influenza season - 2007-2008</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure Immune Response Induced by the Vaccines and Identify Serologic Correlates of Immune Protection</measure>
    <time_frame>one influenza season - 2007-08</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1952</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>TIV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the trivalent inactivated influenza vaccine - Fluzone, manufactured by Sanofi-Pasteur</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LAIV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>live-attenuated influenza vaccine Flumist, manufactured by MedImmune</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Physiologic saline administered as a nasal spray or intramuscular injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluzone</intervention_name>
    <description>single dose licensed trivalent inactivated influenza vaccine (2007-08)</description>
    <arm_group_label>TIV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Flumist</intervention_name>
    <description>single dose licensed live-attenuated influenza vaccine Flumist (2007-08)</description>
    <arm_group_label>LAIV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Physiologic saline</intervention_name>
    <description>single dose placebo administered as an intranasal spray or intramuscular injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult men and women

          -  Age 18-49 years

          -  Who reside geographically close to one of the four study sites in Michigan

        Exclusion Criteria:

          -  Persons with any of the health conditions for which the inactivated vaccine is
             recommended

          -  Persons for whom either vaccine is contraindicated
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnold S. Monto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan School of Public Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan School of Public Heatlh</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Michigan University Health Services</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Michigan University Health Services</name>
      <address>
        <city>Mt. Pleasant</city>
        <state>Michigan</state>
        <zip>48859</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Michigan University Health Services</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ohmit SE, Victor JC, Rotthoff JR, Teich ER, Truscon RK, Baum LL, Rangarajan B, Newton DW, Boulton ML, Monto AS. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med. 2006 Dec 14;355(24):2513-22.</citation>
    <PMID>17167134</PMID>
  </reference>
  <results_reference>
    <citation>Monto AS, Ohmit SE, Petrie JG, Johnson E, Truscon R, Teich E, Rotthoff J, Boulton M, Victor JC. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med. 2009 Sep 24;361(13):1260-7. doi: 10.1056/NEJMoa0808652.</citation>
    <PMID>19776407</PMID>
  </results_reference>
  <verification_date>February 2009</verification_date>
  <lastchanged_date>August 8, 2011</lastchanged_date>
  <firstreceived_date>October 1, 2007</firstreceived_date>
  <firstreceived_results_date>August 8, 2011</firstreceived_results_date>
  <responsible_party>
    <name_title>Arnold S. Monto</name_title>
    <organization>University of Michigan School of Public Health</organization>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Live attenuated influenza vaccine</keyword>
  <keyword>Inactivated influenza vaccine</keyword>
  <keyword>Vaccine Efficacy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fluzone - Trivalent Inactivated Influenza Vaccine</title>
          <description>the trivalent inactivated influenza vaccine - Fluzone, manufactured by Sanofi-Pasteur</description>
        </group>
        <group group_id="P2">
          <title>Flumist - Live-attenuated Influenza Vaccine</title>
          <description>live-attenuated influenza vaccine Flumist, manufactured by MedImmune</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Physiologic saline administered as a nasal spray or intramuscular injection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="814"/>
                <participants group_id="P2" count="813"/>
                <participants group_id="P3" count="325"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="787"/>
                <participants group_id="P2" count="783"/>
                <participants group_id="P3" count="312"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fluzone - Trivalent Inactivated Influenza Vaccine</title>
          <description>the trivalent inactivated influenza vaccine - Fluzone, manufactured by Sanofi-Pasteur</description>
        </group>
        <group group_id="B2">
          <title>Flumist - Live-attenuated Influenza Vaccine</title>
          <description>live-attenuated influenza vaccine Flumist, manufactured by MedImmune</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Physiologic saline administered as a nasal spray or intramuscular injection</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="814"/>
                <measurement group_id="B2" value="813"/>
                <measurement group_id="B3" value="325"/>
                <measurement group_id="B4" value="1952"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="814"/>
                <measurement group_id="B2" value="813"/>
                <measurement group_id="B3" value="325"/>
                <measurement group_id="B4" value="1952"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="23.2" spread="7.4"/>
                <measurement group_id="B2" value="23.5" spread="7.7"/>
                <measurement group_id="B3" value="22.9" spread="6.7"/>
                <measurement group_id="B4" value="23.3" spread="7.4"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="494"/>
                <measurement group_id="B2" value="519"/>
                <measurement group_id="B3" value="201"/>
                <measurement group_id="B4" value="1214"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="320"/>
                <measurement group_id="B2" value="294"/>
                <measurement group_id="B3" value="124"/>
                <measurement group_id="B4" value="738"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="814"/>
                <measurement group_id="B2" value="813"/>
                <measurement group_id="B3" value="325"/>
                <measurement group_id="B4" value="1952"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Laboratory-confirmed (Culture and/or PCR) Symptomatic Influenza</title>
        <time_frame>one influenza season - 2007-2008</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Fluzone - Trivalent Inactivated Influenza Vaccine</title>
            <description>the trivalent inactivated influenza vaccine - Fluzone, manufactured by Sanofi-Pasteur</description>
          </group>
          <group group_id="O2">
            <title>Flumist - Live-attenuated Influenza Vaccine</title>
            <description>live-attenuated influenza vaccine Flumist, manufactured by MedImmune</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Physiologic saline administered as a nasal spray or intramuscular injection</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="814"/>
                  <measurement group_id="O2" value="813"/>
                  <measurement group_id="O3" value="325"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Laboratory-confirmed (Culture and/or PCR) Symptomatic Influenza</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="56"/>
                  <measurement group_id="O3" value="35"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measure Immune Response Induced by the Vaccines and Identify Serologic Correlates of Immune Protection</title>
        <time_frame>one influenza season - 2007-08</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fluzone - Trivalent Inactivated Influenza Vaccine</title>
          <description>the trivalent inactivated influenza vaccine - Fluzone, manufactured by Sanofi-Pasteur</description>
        </group>
        <group group_id="E2">
          <title>Flumist - Live-attenuated Influenza Vaccine</title>
          <description>live-attenuated influenza vaccine Flumist, manufactured by MedImmune</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Physiologic saline administered as a nasal spray or intramuscular injection</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="814"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="813"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain, vomiting, diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Appendicitis, appendectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Appendectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="813"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis, cholecystectomy, cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Cholecystitis, cholecystectomy, cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Mononucleosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>surgical repair of torn ACL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Depression/anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast Cancer/Mastectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="813"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Cervical cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>surgury - remove tumor in left ovary/fallopian tube</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="813"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cellulitis left leg</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="813"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Head injury bike accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Arnold S. Monto, MD</name_or_title>
      <organization>University of Michigan School of Public Health</organization>
      <phone>734-764-5453</phone>
      <email>asmonto@umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
